The International Commission on the Clinical Use of Human Germline Genome Editing has been convened by the U.S. National Academy of Medicine (NAM), the U.S. National Academy of Sciences (NAS), and the Royal Society of the U.K., with the participation of science and medical academies around the world, to develop a framework for scientists, clinicians, and regulatory authorities to consider when assessing potential clinical applications of human germline genome editing. The framework will identify a number of scientific, medical, and ethical requirements that should be considered, and could inform the development of a potential pathway from research to clinical use — if society concludes that heritable human genome editing applications are acceptable.
November 14-15, 2019
2ND COMMISSION MEETING
The second meeting of the commission will take place in London on Nov. 14-15, 2019. View the agenda
August 13, 2019
1ST COMMISSION MEETING
The first meeting of the commission took place at the National Academy of Sciences building in Washington, D.C., on Aug. 13, 2019.
- Agenda (204 KB, PDF)
- Video Recording (Closed captioning available by clicking on the "CC")
- Presentation of the Commission's Statement of Task - Dzau (135 KB, PDF)
- Presentation on World Health Organization Expert Advisory Committee - Hamburg (1.4 MB, PDF)
- Discussion of the State of Understanding of Genetics and Genetic Manipulation - Chakravarti (1.1 MB, PDF)
- Discussion of the State of Understanding of Genetics and Genetic Manipulation - Teichmann (5.2 MB, PDF)
- Discussion of the State of Understanding of Genetics and Genetic Manipulation - Cowan (2.1 MB, PDF)
- Discussion of the State of Understanding of Genetics and Genetic Manipulation - Adamson (1.4 MB, PDF)
- Translational Pathways from Laboratory to Therapy: Somatic Genome Editing - Porteus (2.1 MB, PDF)
- Translational Pathways from Laboratory to Therapy: Somatic Genome Editing - Macrae (3.0 MB, PDF)
- Translational Pathways from Laboratory to Therapy: Somatic Genome Editing - Levine (4.0 MB, PDF)
- Translational Pathways from Laboratory to Therapy: Somatic Genome Editing - Myer (1.3 MB, PDF)
- Translational Pathways from Laboratory to Therapy: Somatic Genome Editing, Perspective from the US FDA - Gavin (344 KB, PDF)
- Translational Pathways from Laboratory to Therapy: Somatic Genome Editing, Perspectives from Potential Patient Communities - Norcross (1.2 MB, PDF)
October 15, 2019, 9:00-10:00AM US ET
Webinar on validating on target and off target edits, featuring Jin-Soo Kim, Seoul National University. Watch the video recording.
October 9, 2019, 10:00-11:00AM US ET
Webinar on homology directed repair and single cell genomics, featuring Shoukhrat Mitalipov, Oregon Health & Science University and Xiaoliang Sunney Xie, Peking University. Watch the video recording.
October 7, 2019
Webinar on the impact of editing on embryo viability and editing spermatogonial stem cells, featuring Kathy Niakan, Francis Crick Institute and Kyle Orwig, Magee-Womens Research Institute. Watch video recording
October 4, 2019
Webinar on informed consent in the context of germline genome editing, featuring Ellen Clayton, Vanderbilt University and Robert Klitzman, Columbia University. Watch video recording
The commission is the latest action from the international science community to address issues around human genome editing. It follows the Second International Summit on Human Genome Editing — held last November in Hong Kong by NAS, NAM, the Royal Society, and the Academy of Sciences of Hong Kong. The topic became a focus of global attention when a scientist from China revealed at the summit that as a result of his research, twins had been born whose embryonic genomes had been edited. The scientist was widely condemned by the global scientific community for violating long-standing scientific principles and ethical norms.
The U.S. National Academies and the Royal Society are the secretariat of the commission, which includes representatives from 10 nations. Kay Davies, professor of genetics at the MDUK Oxford Neuromuscular Centre at the University of Oxford, England, and Richard Lifton, president of the Rockefeller University in New York City, are co-chairs of the commission. The commission will hold one additional meeting and an international workshop, and will also issue a call for public input to inform their work. A final report from the commission is expected to be issued in the spring of 2020.
- Commission Members and Biographies
- Statement of Task
- International Oversight Board
- Press Release
- Call for Evidence Question List - thanks all those who provided information in response to the call for evidence.
- Royal Society Commission Website
- Subscribe to Our Mailing List for Updates
Email questions to firstname.lastname@example.org.
Financial support for the Commission is being provided by the U.S. National Institutes of Health, The Rockefeller Foundation, The Wellcome Trust, the Royal Society of the U.K., the Cicerone Endowment Fund of the U.S. National Academy of Sciences, and the NAM Initiatives Fund of the U.S. National Academy of Medicine.